Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse

Mantle Cell Lymphoma Clinical Trial

— OPERA-PLRG10  

Official title:

Evaluation of Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell (ML29157).

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03229382
• Other study ID #: ML29157
• Secondary ID: 2015-005439-41
• Status: Terminated
• Phase: Phase 2
• Start date: May 14, 2018
• Est. completion date: January 31, 2020

Study information

• Verified date: August 2023
• Source: Polish Lymphoma Research Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is the evaluation of efficacy and safety of obinutuzumab preemptive treatment at the time of the molecular relapse after first line immunochemotherapy with autologous stem cell transplantation in mantle cell lymphoma patients.

Description:

Patients with evidence of MCL molecular relapse defined as an increasing copy number in quantitative real-time polymerase chain reaction (RQ-PCR) of clone-specific immunoglobulin heavy chain (IGH) gene rearrangements or BCL1-IGH fusion genes according to BIOMED-2 methodology and protocols in peripheral blood or/and bone marrow without evidence of clinical relapse/progression after auto-HCT procedure with all inclusion and no exclusion clinical trial criteria will receive 4 weekly infusions of obinutuzumab (1000 mg, iv) on day 1, 8, 15, 22.Response assessment in bone marrow and/or peripheral blood and CT/MRI imaging will be performed 2 months after the obinutuzumab preemptive treatment. Patients with subsequent molecular remission in peripheral blood and/or bone marrow confirmed in RQ-PCR (with 10-4 level of sensitivity) assessment and no signs of relapse/progression according to the Lugano Classification will be further followed. From this moment, evaluation of response will be performed every 6 months with computed tomography/magnetic resonance (CT/MR) imaging and bone marrow aspiration to detect classical relapse/progression and/or to detect subsequent molecular relapse by quantitative real-time polymerase chain reaction (RQ-PCR) of clone-specific immunoglobulin heavy chain (IGH) gene rearrangements or BCL1-IGH fusion genes with the use of consensus JH probes and specific ASO primers. Patients will be monitored every 3 months (outpatient visits with peripheral blood samples for MRD assessment to detect molecular relapse by quantitative RQ-PCR of clone-specific immunoglobulin heavy chain (IGH) gene rearrangements or BCL1-IGH fusion genes). Preemptive treatment can be administered in subsequent molecular relapses/progressions.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: January 31, 2020
• Est. primary completion date: January 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients with evidence of MCL molecular relapse in peripheral blood or/and bone marrow,
• Diagnosis of mantle cell lymphoma confirmed by histopathology
• Presence of clone-specific immunoglobulin heavy chain (IGH) gene rearrangements or BCL1-IGH fusion gene as a molecular marker used for minimal residual disease (MRD) assessment,
• Patients in CR/PR after first-line treatment with myeloablative consolidation and ASCT,
• Patients without evidence of mantle cell lymphoma progression/relapse according to the Lugano Classification criteria (2014),
• ECOG performance status = 2,
• Signed patient's informed consent form,
• Survival prognosis > 6 months,
• Women of childbearing potential must have a negative pregnancy test result prior to initiation of treatment with the study medication and must consent to undergo pregnancy tests during the treatment period.,
• Women of child-bearing potential must consent either to sexual abstinence or to using effective contraception (that results in a failure rate of < 1% per year) while receiving the study medication and for 18 months after its discontinuation,
• Men must consent either to using an acceptable contraception method (that results in a failure rate of < 1% per year) or continued sexual abstinence while receiving the study medication and for 6 months after its discontinuation.

Exclusion Criteria:

• Central nervous system involvement,
• Chemotherapy, radiation therapy or any other antineoplastic treatment (including steroids, monoclonal antibodies or medications at the stage of clinical studies, before receiving marketing authorisation) after ASCT and before administration of the study medication,
• Major surgery within 28 days prior to the study treatment initiation,
• Renal impairment (plasma creatinine concentration > 1.5 × upper limit of normal and/or creatinine clearance = 40 ml/h),
• Hepatic impairment (total bilirubin concentration > 1.5 × upper limit of normal, AST and ALT > 2.5 × upper limit of normal),
• Hb< 9 g/dl, ANC < 1.5 G/l, platelets < 75 G/l,
• International normalized ratio (INR) > 1.5,
• Clinically significant heart disease, including uncontrolled arrhythmias, unstable coronary artery disease, serious congestive circulatory failure (NYHA III-IV), myocardial infarction within 6 months before enrolment,
• Other comorbidities, not responding to treatment, including, but not limited to:

hematopoietic system diseases, gastrointestinal system diseases, endocrine system diseases, respiratory system diseases, neurological diseases, cerebral diseases and mental diseases that could affect compliance with the protocol or interpretation of results,

• Active infections (viral, bacterial, fungal),
• Coexistence of another neoplasm or a history of neoplastic disease (except for adequately treated basal cell carcinoma or squamous cell skin carcinoma, in situ cervical cancer or other neoplasm if the patient is in complete remission after at least 5 years of treatment discontinuation),
• Active HIV, HBV or HCV infection,
• Positive test results for chronic hepatitis B. All patients must be tested for both HBsAg and HBcAb at screening, if either of the tests is positive, the patient is not eligible for inclusion in the trial. Patients who have protective titers of HBsAb after vaccination are eligible provided they are negative for both HBsAg and HBcAb,
• Positive testing for hepatitis C (hepatitis C virus [HCV] antibody serology testing). Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA,
• Vaccination with live vaccines within 28 days prior to start of the preemptive treatment,
• Known or suspected hypersensitivity to the study medication,
• Women who are pregnant or breastfeeding.

Related Conditions & MeSH terms

• Lymphoma, Mantle-Cell
• Mantle Cell Lymphoma

Intervention

Drug:
• Obinutuzumab
Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.

Locations

Country	Name	City	State
Poland	Centrum Onkologii - Instytut im. Marii Sklodowskiej- Curie Klinika Nowotworów Ukladu Chlonnego	Warszawa

Sponsors (2)

Lead Sponsor	Collaborator
Polish Lymphoma Research Group	Roche Pharma AG

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MRD negativity defined as a MRD level	Molecular response rate (molRR) defined as a rate of molecular response with at least 10-4 sensitivity level assessed by quantitative RQ-PCR	2 months after obinutuzumab treatment
Secondary	Progression-free survival (PFS)	defined as the time from the date of the first obinutuzumab infusion to disease progression or relapse, as determined by the investigator using the Lugano Classification or death from any cause after the last dose of study drug	3 years and 2 month
Secondary	Time to molecular relapse	as the time from the date of the first obinutuzumab infusion to the first occurrence of molecular disease relapse	3 years and 2 month
Secondary	Overall survival (OS)	defined as the time from the date of the initiation of the first line treatment to the death from any reason	3 years and 2 month
Secondary	Time to relapse/progression	defined as the time from the date of the first obinutuzumab infusion to the first evidence of disease progression or relapse, as determined by the investigator using the Lugano Classification	3 years and 2 month
Secondary	Event-free survival (EFS)	defined as the time from the date of the first obinutuzumab infusion to the first evidence of disease progression or relapse (as determined by the investigator using the Lugano Classification), death from any reason, start of the another anti-lymphoma treatment, SAE preventing continuation of the protocol treatment	3 years and 2 month
Secondary	Health status measured with EQ-5D from EuroQoL Group	with EQ-5D from EuroQoL Group	3 years and 2 month
Secondary	Treatment tolerability assessment	reporting of serious adverse events (SAEs), adverse events (AEs) and adverse events of special interest	3 years and 2 month